

AUDITORS' CONSENT

We have read the prospectus supplement of Algernon Pharmaceuticals Inc. (the "Company") dated December 23, 2022 relating to the "at-the-market" distribution by the Company of up to \$5,000,000 of common shares of the Company, to the short form base shelf prospectus dated May 5, 2021 of the Company, (the prospectus supplement and the short form base shelf prospectus are collectively referred to as the "Prospectus"). We have complied with Canadian generally accepted standards for an auditor's involvement with offering documents.

We consent to the incorporation by reference in the above-mentioned Prospectus of our auditors' report to the shareholders of the Company on the consolidated statement of financial position of the Company as at August 31, 2022 and 2021, and the consolidated statements of loss and comprehensive loss, changes in equity and cash flows for each of the years then ended. Our report is dated November 21, 2022.

Smythe LLP

Chartered Professional Accountants
Vancouver, British Columbia

December 23, 2022

VANCOUVER

1700-475 Howe St
Vancouver, BC V6C 2B3
T: 604 687 1231
F: 604 688 4675

LANGLEY

600-19933 88 Ave
Langley, BC V2Y 4K5
T: 604 282 3600
F: 604 357 1376

NANAIMO

201-1825 Bowen Rd
Nanaimo, BC V9S 1H1
T: 250 755 2111
F: 250 984 0886